Clinical trials: Small Cell Carcinoma of Lung
Small Cell Lung Carcinoma
Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer
This is a multi-center, open-label, non-randomized Phase I study to define the safety profile, maximum tolerated dose (MTD) and potential pharmacokinetic interaction of regorafenib in combination with pemetrexed and cisplatin in…
- Trial name
- NCT01187615
- Testing
- Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed, Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Bayer
Non Small Cell Lung Cancer
Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer
This is a multicentre randomised double-blind phase II trial, sponsored by Gustave Roussy and involving one French center as well as the Spanish Lung Cancer Group (≈20 centers of the SLCG).
- Trial name
- PIPSeN (NCT02679963)
- Testing
- Olaparib
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
NSCLC
Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
Patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with brain metastases remain a major clinical challenge.
- Trial name
- NCT07413952
- Testing
- Limertinib Plus Radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Carcinoma, Non-Small-Cell Lung
TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV
This study wants to determine the activity of a first-line treatment related to Thymidylate Synthetase (TS) Expression. Patients with the diagnosis of non-squamous advanced Non-Small-Cell Lung-Cancer (Stage IV) and without…
- Trial name
- SELECT-A (NCT01674738)
- Testing
- Pemetrexed, Cisplatin, Bevacizumab
- Sponsor
- Aktion Bronchialkarzinom e.V.
Small-cell Lung Cancer
Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
The SPACE-T study is a clinical trial for people with advanced small-cell lung cancer (SCLC) whose cancer has returned or spread despite previous treatment and whose general health is reduced (ECOG performance status 2).
- Trial name
- SPACE-T (NCT07803848)
- Testing
- Tarlatamab
- Where
- 8 sites in Germany
- Volunteers
- 57 people
- Sponsor
- AIO-Studien-gGmbH
Primary Lung Cancer
Circulating Tumor Cells in Non-Small Cell Lung Carcinoma
The purpose of this study is to establish the circulating tumor cell (CTC) assay as a surrogate for tissue diagnosis of suspected primary lung cancer.
- Trial name
- LDx (NCT01830426)
- Where
- 3 sites in United States
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Epic Sciences
Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer Stage
Metabolic and Microbial Profiling of Lung Cancer
This pilot study will establish non-invasive sample collections, including breath, saliva, blood and urine pre-surgery and at the participant's one-month post-surgery follow-up visit.
- Trial name
- NCT03998189
- Testing
- Breath Collection, Saliva Collection, Blood Collection
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Neoplasms
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited…
- Trial name
- GARNET (NCT02715284)
- Testing
- Dostarlimab
- Where
- 128 sites in United States, Argentina and 11 more
- Volunteers
- 729 people
- Sponsor
- Tesaro, Inc.
Nodule Solitary Pulmonary, Non-small Cell Lung Cancer
Biomarkers for Risk Stratification in Lung Cancer
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco…
- Trial name
- NCT03774758
- Testing
- Guardant Health ct-DNA LUNAR assay
- Where
- 3 sites in United States
- Volunteers
- 1,440 people
- Sponsor
- University of California, San Francisco
Non-small Cell Lung Cancer
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
This is a study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab (MK-3475, KEYTRUDA®) in adults with first line metastatic squamous non-small cell lung cancer…
- Trial name
- NCT02775435
- Testing
- Pembrolizumab, Paclitaxel, Nab-paclitaxel
- Volunteers
- 559 people
- Sponsor
- Merck Sharp & Dohme LLC
Small Cell Lung Cancer
Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer
This study is aimed to evaluate the progression-free survival(PFS) and also survival of IP and EP (head-to-head) as the first line therapy for extensive stage small-cell lung cancer and to explore the reasonable first-line…
- Trial name
- NCT02348450
- Testing
- Irinotecan, Etoposide, Cisplatin
- Where
- 20 sites in China
- Volunteers
- 308 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-small Cell Lung Cancer, Postmenopausal Women
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer
This research study will test whether dual anti-estrogen therapy (anastrozole and fulvestrant) slows the time to when the cancer progresses.
- Trial name
- NCT00932152
- Testing
- fulvestrant (Faslodex), anastrozole (Arimidex), Bevacizumab (Avastin)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pittsburgh
NSCLC
Iressa as Second Line Therapy in Advanced NSCLC-Asia
This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational…
- Trial name
- ISTANA (NCT00478049)
- Testing
- Gefitinib, Docetaxel
- Where
- 4 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor, Non-small Cell Lung Cancer
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2…
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma
- Trial name
- NCT04442126
- Testing
- NM21-1480
- Where
- 26 sites in United States, Spain and 1 more
- Volunteers
- 52 people
- Sponsor
- Numab Therapeutics AG
Carcinoma, Non-Small-Cell Lung
A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung Cancer
The purpose of this study is to describe the real-world patient and disease characteristics of metastatic non-small cell lung cancer (NSCLC) participants initiated on first-line (1L) treatment with nivolumab, ipilimumab, and…
- Trial name
- AURORA (NCT05599685)
- Where
- Greece
- Volunteers
- 302 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
This phase Ib trial studies the best way of TLR8 Agonist VTX-2337 and cyclophosphamide in treating patients with a solid tumor that has spread from the primary site (place where it started) to other places in the body…
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma
- Trial name
- NCT02650635
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Non-small Cell Lung Cancer, Melanoma
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17 vs.
- Conditions
- Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT07160335
- Testing
- HLX17, US-sourced Keytruda®
- Where
- 69 sites in United States, China and 2 more
- Volunteers
- 174 people
- Sponsor
- Shanghai Henlius Biotech
Non-Small Cell Lung Cancer
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study will evaluate the pharmacokinetics, safety, and efficacy of atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV) in participants with locally advanced or metastatic Non-Small Cell Lung Cancer…
- Trial name
- NCT03735121
- Testing
- Atezolizumab, rHuPH20
- Where
- 74 sites in Argentina, Brazil and 21 more
- Volunteers
- 438 people
- Sponsor
- Hoffmann-La Roche
Non-small-cell Lung Cancer
Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC
This trial will compare the efficacy of the docetaxel and gemcitabine combination versus monotherapy with gemcitabine as first-line treatment in elderly patients with advanced NSCLC
- Trial name
- NCT00442026
- Testing
- Docetaxel, Gemcitabine
- Where
- 9 sites in Greece
- Volunteers
- 106 people
- Sponsor
- Hellenic Oncology Research Group
Lung Cancer
Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy
RATIONALE: Vaccines made from a person's tumor cells may help the body build an effective immune response to kill non-small cell lung cancer cells.
- Trial name
- NCT00503568
- Testing
- Ad100-gp96Ig-HLA A1
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Miami
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.